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To date, randomized controlled clinical trials performed in pulmonary arterial hypertension
(PAH) have been relatively short-term studies involving mainly patients with advanced
disease. The primary end points in these trials have addressed exercise capacity, usually by
using the 6-min walk test. Although this approach is still warranted in future trials assessing
new treatments, it is likely that the focus will shift toward trials of longer duration, involving
patients with less advanced disease, and that different drugs and drug-combination regimens
will be compared. In such trials, it is possible that a composite of markers indicating clinical
deterioration (e.g., hospitalization for right heart failure, the requirement for the introduction
of an alternative treatment, and predefined indicators of worsening exercise tolerance) may be
more useful as primary end points. Quality of life will become a very important issue; however,
appropriate quality-of-life questionnaires for PAH have yet to be developed. In addition,
hemodynamics will likely remain valuable as secondary end points, but future clinical trials
should include hemodynamics obtained both during exercise and at rest. Finally, cardiopul-
monary exercise testing, echocardiographic studies, and biochemical parameters, such as brain
natriuretic peptide or troponin T, may also prove useful as secondary end points in the
future. (J Am Coll Cardiol 2004;43:48S–55S) © 2004 by the American College of
Cardiology Foundationr
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Peven randomized, placebo-controlled trials of medical
reatments for pulmonary arterial hypertension (PAH) have
een published in recent years (1–7). In all of these trials,
xercise-related measurements were used as primary end
oints, the most common measurement being the 6-min
alk test (8). If the goal of a clinical trial is to convince
atients, physicians, funding agencies, and regulatory bodies
f the value of treatments, which are often expensive, it is
orth considering whether other end points should be
xamined that more adequately describe changes occurring
ith these treatments. From patients’ perspectives and
ncreasingly from the perspective of regulatory agencies,
uality of life (QoL) is likely to be one of the most
mportant measures of success or failure of a particular
reatment. However, some clinicians treating PAH may not
e satisfied with improvements in QoL alone; many might
eed to see physiological improvements such as changes in
ulmonary hemodynamics, exercise physiology, circulating
ormones, or cardiopulmonary morphology. Evidence of
ncreased survival is highly desirable.
The choice of appropriate end points for clinical trials in
AH should also take into account the requirements of
From the *Department of Respiratory Medicine, Hannover Medical School,
annover, Germany; †Division of Cardiology, Harbor—UCLA Medical Center,
orrance, California; ‡Scottish Pulmonary Vascular Unit, Glasgow, Scotland; §Pul-
onary Hypertension Center, Duke University Medical Center, Durham, North
arolina; Institute of Child Health, London, United Kingdom; ¶Baylor College of
edicine, Houston, Texas; and #Institute of Tuberculosis and Lung Diseases,
niversity of Warsaw, Warsaw, Poland.aManuscript received November 26, 2003; accepted February 3, 2004.egulatory agencies, which usually are the ultimate referees
n the approval process of a particular treatment.
In the process of decision making for the implementation
f new trials for PAH, it appears that the two main issues
hat need to be addressed are the trial design and the choice
f the appropriate primary and secondary reinforcing end
oints.
The views presented here are a summary from the Third
orld Symposium on Pulmonary Hypertension, held in
enice, Italy, in 2003, and from an expert symposium held
ust prior to this meeting in Gleneagles, Scotland, in 2003,
n order to prepare the topic of “Endpoints in PAH” for the
enice meeting. Participants of the task force on medical
reatment and end points in Venice and the participants of
he Gleneagles meeting are listed in the appendix.
LINICAL TRIAL DESIGN
fter the regulatory approval of oral bosentan for the
reatment of New York Heart Association/World Health
rganization (NYHA/WHO) functional class III and IV
AH patients, and after additional oral compounds became
vailable for clinical studies in PAH, several key questions
ave arisen: 1) are placebo-controlled studies still possible to
ssess these new compounds? 2) are noninferiority studies
easible? 3) are withdrawal studies ethical? and 4) how
hould combination therapies be addressed? All of these
uestions are examined below.
lacebo-controlled studies. Currently, four treatments are
pproved either by American (Food and Drug Administra-
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June 18, 2004:48S–55S Trial Designs in PAHion; FDA) or European (European Agency for the Evalu-
tion of Medicinal Products; EMEA) regulatory agencies
or the treatment of PAH patients: intravenous epoproste-
ol for primary pulmonary hypertension (PPH) patients
ith NYHA/WHO functional class III and IV symptoms
FDA and EMEA), subcutaneous treprostinil for PAH
atients with NYHA/WHO functional class II, III, and IV
ymptoms (FDA), oral bosentan for PAH patients with
YHA/WHO functional class III symptoms (EMEA) and
lass III and IV symptoms (FDA), and inhaled iloprost for
PH patients with NYHA/WHO functional class III
ymptoms (EMEA). Only epoprostenol treatment has been
hown to improve survival in a randomized, controlled
linical trial (9). Treprostinil, inhaled iloprost, and bosentan
ave been shown to reduce clinical events, but none of them
mproved mortality after three to four months in the
andomized trials (2,4,6). Patients enrolled in these latter
tudies were less compromised compared with patients in
he epoprostenol study. These trials were clearly not pow-
red for detecting any effect on mortality owing to the small
ample size and the short duration of the studies.
From ethical and methodological perspectives, it might
e suggested that a mortality study in PAH patients with
YHA/WHO functional class III and IV symptoms can
nly be performed using intravenous epoprostenol as the
omparator, because only this drug has been shown to
mprove mortality.
Less clear is whether a placebo-controlled study whose
rimary end point is exercise capacity assessed after three to
our months of a randomized treatment would still be
cceptable, both to clinicians and regulatory authorities.
easons supporting the continued use of placebo in ran-
omized trials include the following: 1) prognostic superi-
rity has not been demonstrated by any of the newer PAH
rugs beyond the three to four months of randomized trial
eriods (mortality ranging from 1% to 3%, corresponding to
% to 12% per year); 2) the setting of a controlled clinical
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CO  cardiac output
CPET  cardiopulmonary exercise testing
EMEA  European Agency for the Evaluation of
Medicinal Products
FDA  Food and Drug Administration
LV  left ventricle/ventricular
NYHA  New York Heart Association
PAH  pulmonary arterial hypertension
PAP  pulmonary artery pressure
PAPm  mean pulmonary artery pressure
PCWP  pulmonary capillary wedge pressure
PVR  pulmonary vascular resistance
QoL  quality of life
RV  right ventricle/ventricular
VO2  oxygen consumption
WHO  World Health Organizationrial protects patients by allowing them to be shifted to clready approved treatments in case of deterioration; 3)
YHA/WHO functional class II patients have been only
inimally involved in clinical trials in PAH, and are
xcellent candidates for placebo-controlled trials; and 4)
here is no cure for PAH, and a consistent proportion of
atients fail to respond to all available treatments. There-
ore, hurdles should not be set too high for the investigation
f new treatments.
In contrast, potential problems with continuing placebo-
ontrolled studies include the following: 1) it may be
onsidered unethical to expose patients to three to four
onths of placebo when symptomatic and clinical deterio-
ation is known to occur in such time; 2) NYHA/WHO
unctional class II patients appear to be a “minority” in the
opulation observed in clinical practice; and 3) the current
riority in clinical practice might be one of comparison of
ew treatments with approved ones.
Weighing these arguments, the working groups in Scot-
and and Italy concluded that, given the outlined conditions,
lacebo-controlled trials for shorter periods of time (up to
our months) are still justified from an ethical and scientific
oint of view.
oninferiority studies. Noninferiority comparative studies
an be an alternative to superiority placebo-controlled stud-
es if the latter are considered inappropriate for ethical
nd/or practical reasons. In fact, comparative studies de-
igned to demonstrate superiority would be difficult to
erform in a rare disease like PAH because the required
ample size would be quite large, relative to the disease
revalence. The objective of a noninferiority study is to
emonstrate that no statistically significant difference
xists between two compounds for a given end point.
herefore, noninferiority studies can only be performed
ith established primary end points that have already
een investigated.
Noninferiority studies also require a setting identical to
hat of the pivotal study of the comparator (inclusion
riteria, exclusion criteria, patient population, study proto-
ol, among others). If the comparator were bosentan, for
xample, the study design would require that the 6-min
alk test be used as the primary end point, as it was in the
ivotal study of bosentan (2). Although a superiority study
ver bosentan would be prohibitive in terms of sample size,
n the above scenario, the sample size would also need to be
uite high (500 patients), so that even noninferiority trials
ear considerable risks and costs for the sponsors.
ithdrawal studies. Withdrawal studies can be suggested
y regulatory agencies for different reasons. For example,
hen pivotal trials have not shown a clinically relevant
enefit, or a more consistent proof of efficacy is required, the
DA may suggest or require that a withdrawal study be
erformed before granting regulatory approval. In a life-
hreatening disease such as PAH, a withdrawal study might
e considered inappropriate for several reasons. Withdrawal
f an effective drug may cause clinical deterioration, which
ould be irreversible and life-threatening even if the previ-
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Trial Designs in PAH June 18, 2004:48S–55Sus treatment were to be reinstituted. As a consequence, the
nd point of such a study would be to assess clinical
orsening. This could be considered against the basic
edical principle, primum non nocere (“First, do no harm”).
or these reasons, approval of such a study by institutional
eview boards and patient acceptance of such a trial would
e difficult.
During the Venice symposium, the Endpoints Task
orce members concluded that withdrawal studies should
ot be recommended in PAH patients with functional class
II or IV symptoms who are receiving a single active
reatment that has proven to be effective in randomized,
lacebo-controlled trials. However, withdrawal studies may
e a useful means to study the efficacy of combination
herapies (see the following text).
ombination therapies. Given that no currently available
AH treatment offers the potential for cure or long-term
tabilization for the majority of PAH patients (other than
ung transplantation) (10–12), it is likely that a combination
f active treatments will be used increasingly in the near
uture. Preliminary studies suggest that combinations of
rostanoids and phosphodiesterase inhibitors or prostanoids
nd endothelin receptor antagonists are safe and effective in
elected PAH patients (13,14). However, for reasons con-
erning efficacy, safety, and costs, it is imperative that
ombination treatments are carefully investigated. As stated
bove, one useful means to study combination treatments
ould be withdrawal studies. Alternatively, combinations of
wo (or more) compounds could be studied in an add-on
esign, using classical end points. Provided that the sample
ize is high enough, even more information might be
erived from three-arm studies including both compounds
lone and in combination.
RIMARY AND SECONDARY
EINFORCING END POINTS ACCORDING TO
EQUIREMENTS OF REGULATORY AGENCIES
or PAH, it appears that regulatory agencies are currently
ccepting as “primary” end points only traditional clinical
nd points such as exercise capacity, QoL, time to clinical
orsening and mortality. Usually, physiologic parameters
uch as hemodynamics are considered “secondary.”
In PAH trials, assessment of exercise capacity using the
-min walk test can still be considered a good choice for a
rimary end point for several reasons, including the possi-
ility to compare the results with previous trials. However,
t is important that the clinical relevance of a given improve-
ent in the distance walked is defined a priori in the
rotocol of the study to avoid inconclusive discussions at the
nd of the trial. This might be accomplished by defining
linical relevance according to the treatment effect obtained
ith already approved treatments, because the term “clinical
elevance” can be somewhat arbitrary.
Quality of life as a primary end point has been proposed,ut concerns include the lack of validation that has been trovided for this parameter in PAH thus far (see the
ollowing text).
Time to clinical worsening as a combined end point
equires standardization to make the end point more objec-
ive and comparable. This parameter has most often been
efined in PAH trials as the combination of death, hospi-
alizations due to worsening of PAH, and escalation of
reatments (need for epoprostenol or lung transplantation).
he last two events are influenced by the judgment of the
ttending physician, and as an end point it should be
upported by some objective findings, such as predefined
hresholds defining deterioration in exercise capacity or
emodynamic parameters.
Hemodynamic parameters have traditionally been con-
idered as “secondary,” or reinforcing end points, based on
heir prognostic value (15), and this concept has been
ccepted by regulatory agencies. The Endpoints Task Force
embers agreed that using selected echocardiographic pa-
ameters as noninvasive substitutes of hemodynamics should
e explored.
The usefulness of biological markers as end points for
linical trials, such as brain natriuretic peptide (BNP),
roponin, and endothelin, has yet to be tested and validated
n clinical studies, and thus, at present, cannot be proposed
o regulatory agencies as primary end points.
ND POINTS IN CLINICAL TRIALS
ccording to the Venice task force, an end point may be
efined as a measurement used by investigators conducting a
linical trial to determine whether patients benefited from drug
dministration. The choice of an end point should reflect the
esired therapeutic goals. In PAH patients with NYHA/
HO functional class III or IV symptoms, improvement of
xercise capacity may be considered a primary therapeutic
oal, and thus end points addressing exercise tolerance may
e appropriate. In patients with NYHA/WHO functional
lass I and II symptoms, slowing or stopping progression of
isease may be considered the primary goal. Most of the
linical trials in PAH performed thus far have included
ainly patients with NYHA/WHO functional class III
ymptoms; however, it is likely that the focus of clinicians
reating PAH will shift to early detection of pulmonary
ypertension in patients with less severe disease. Thus, in
uch a scenario it is critical that end points are chosen that
eflect clinical stability, that is, lack of deterioration.
linical end points. Clinically relevant events such as
eath, hospitalization for right heart failure, or the require-
ent for the introduction of alternative (“rescue”) treat-
ents have been widely used as secondary, often combined,
nd points in most of the randomized clinical trials of PAH
reatments. In those studies, which included mainly class III
nd IV patients, the active treatments were able to show a
ignificant reduction of these events after the three- to
our-month study periods (2,6,9). However, it is anticipated
hat observation periods will have to be much longer when
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June 18, 2004:48S–55S Trial Designs in PAHatients with less advanced illness are being studied or when
ifferent active treatments are being compared to each
ther, or combined. In these circumstances, it is important
or safety reasons that clinical end points encompass not
nly the aforementioned indicators of severe complications
ut also encompass other variables that define clinical
eterioration, such as a predefined decline in 6-min walk
istance or in peak oxygen consumption. One suggested
ombined end point might combine all of the above
ariables, and be termed failure-free survival.
xercise studies: 6-min walk test and cardiopulmonary
xercise testing (CPET). Assessment of functional capac-
ty in both clinical and research applications is an important
ool for evaluating disease severity. The most widely used
est to assess exercise capacity in PAH patients has been the
-min walk test, the main advantage being its ease of
dministration. The 6-min walk test correlates with several
arameters of CPET and provides important prognostic
nformation (10,16). Paciocco et al. (17) showed an 18%
eduction in the risk of death per additional 50 m walked in
atients with PPH performing the 6-min walk test.
The 6-min walk test has also been successfully used in
cleroderma-associated pulmonary hypertension (18) and in
he Eisenmenger syndrome (19), but there has been no
tudy of the 6-min walk test for portopulmonary hyperten-
ion patients. In addition, the 6-min walk test has not been
alidated as an end point in PAH patients with less severe
isease (i.e., NYHA/WHO functional class I and II symp-
oms).
Measurement of ventilation and pulmonary gas exchange
uring exercise testing provides additional information to
hat derived from standard exercise testing. This modality
CPET) offers an objective evaluation of functional capacity
nd provides information beyond that of most traditional
xercise tests, some of which are independent of patient
ffort. Although the peak oxygen consumption (VO2) may
e limited by factors other than circulatory impairment, it is
ery helpful in describing the magnitude of exercise limita-
ions in comparison to normal controls. During submaximal
xercise, anaerobic or lactic acid threshold can be obtained
s a surrogate for peak VO2, and may reflect circulatory
imitations. Finally, the slope of VE/VCO2 or the VE/VCO2
atio measured at the anaerobic threshold is nearly always
levated in patients with PAH, and reflects the impaired
ulmonary circulation that is the hallmark of PAH (20).
Several studies of CPET in PAH have significantly
ontributed to our understanding of the symptoms and
athophysiology of patients with PAH who experience
yspnea during exercise (20,21). In addition, Wax et al. (22)
howed that in 16 PPH patients undergoing CPET, peak
O2 and O2 pulse increased significantly after two years of
reatment with intravenous epoprostenol. Wensel et al. (23)
ound that baseline peak VO2 and the baseline maximum
ystolic blood pressure during exercise were strong and
ndependent predictors of survival.The 6-min walk test has been used successfully as primary pnd point in many clinical studies in PAH (3,4,18,24) and
s, to date, the only measure of exercise capacity that has
een accepted by the FDA, based on its validation as a
arker of a treatment effect. In contrast, presently there is
imited experience with the use of CPET in multicenter
rials. In one recent multicenter study on beraprost in PAH
atients, the 6-min walk test revealed a significant improve-
ent after three and six months of treatment, whereas there
ere no significant changes in CPET variables (5). These
esults raised several questions and concerns about the
uality of the CPET studies performed at each study center,
specially as the 6-min walk test itself was used as a
urrogate for CPET, based on its correlation with peak VO2.
t appears that the results of CPET were largely influenced
y the experience of the involved centers, whose variability
as probably related to the interpretation of the CPET
tudies rather than to the performance of the studies. For
hese reasons, the Endpoints Task Force members believe
hat CPET cannot currently be recommended as a primary
nd point in multicenter trials on new treatments for PAH.
owever, the use of a core CPET laboratory might avoid
rrors in interpretation made at individual study centers.
inally, because of the substantial physiologic information
rovided by CPET, this technique might be used in
ubstudies involving centers with experience in CPET in
rder to generate secondary end points in forthcoming
tudies.
he NYHA and WHO functional classification. The
YHA functional classification system is widely used as a
arker of disease severity in cardiovascular disease (25).
ne of the simplest and crudest assessments of exercise
apacity, the NYHA functional classification has been
hown to correlate with disease severity and outcome in a
ultitude of cardiopulmonary disorders, including PPH
10,15). The WHO functional classification system for
AH (26) is an adaptation of the NYHA system. It is nearly
dentical to the original NYHA functional classification
ext, with the references to cardiac-specific symptoms such
s the deletion of angina, and the addition of references to
AH-related symptoms. In practice, many clinicians refer
o both classification systems collectively as NYHA/WHO
unctional classification.
A major limitation to the NYHA and WHO functional
lassification systems is that they rely upon patients to report
heir own limitations. Patients who over- or under-report
heir physical limitations can lead the clinician to make
ncorrect conclusions about their patient’s disease severity.
n addition, even despite widely accepted definitions, great
ariability exists in how physicians assign functional classi-
cation. It appears that the vast majority of PAH patients
eported in the published reports have been classified as
aving NYHA/WHO functional class III symptoms. It is
lso evident that this classification may not be revised by
reating clinicians even when medical treatments result in
ubjective and objective functional improvements. A tighter,
erhaps subdivided, categorization should be developed and
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Trial Designs in PAH June 18, 2004:48S–55Salidated. In the current version, the NYHA/WHO func-
ional classification may be too crude to be used as a primary
nd point in clinical trials, though it has been utilized
uccessfully as part of a combined primary end point (6). It
s likely that functional classification will remain in use as a
econdary, reinforcing end point in future clinical trials.
ahler dyspnea index. The Mahler dyspnea index has
een used in chronic lung disease (27) and in pulmonary
ypertension (6). Compared to the NYHA and WHO
unctional classification systems, it provides a scale from 0 to
2 with equal contributions of functional impairment,
agnitude of task, and magnitude of effort until dyspnea
ccurs. Systematic comparisons between the Mahler dys-
nea index and 6-min walk test or CPET have not been
ade.
emodynamics. Progressive remodeling of the pulmonary
rteriolar vessels causes an increase in pulmonary vascular
esistance (PVR), which increases right ventricular (RV)
fterload. Patients become symptomatic mainly because of
he inability of their RV to overcome the increased RV
fterload, and thus they are unable to adequately increase
ulmonary blood flow (cardiac output) for the O2 exercise
emand. Accordingly, a right heart catheterization with
easurements of pulmonary vascular pressures and blood
ow quantify both the disease process (PVR) and its main
unctional consequence (cardiac output [CO] limitation). It
s therefore understandable that standard hemodynamic
easurements in patients with PAH correlate with clinical
tate, functional class, exercise capacity, and prognosis
10,11,15). However, there has been disappointment related
o the fact that these correlations are loose, and that mean
ulmonary artery pressures (PAPs) often fail to reach
tatistically significant correlation with outcome in PAH
reatment trials. As such, standard invasive pulmonary
emodynamic measurements have not been considered as a
rimary end point in randomized controlled trials of new
harmacological approaches to PAH therapy. In fact, there
s a current tendency to omit hemodynamic measurements
ven as a secondary end point. The End Points Task Force
elieve, however, that a right heart catheterization with
ulmonary hemodynamic measurements should be required
oth for confirming the initial diagnosis of PAH and for
valuating the progression and response to therapy in PAH
atients.
The reasons why pulmonary hemodynamic measure-
ents do not appear to be tightly correlated to clinical state
n patients with PAH are twofold. First, in most reported
tudies, measurements are performed at rest only, when RV
tress and related symptoms are minimal. Second, mean
ulmonary artery pressure (PAPm) and CO determinations
ay be insufficient to accurately reflect RV afterload.
A single-point measurement of PAPm, pulmonary cap-
llary wedge pressure (PCWP), and CO, and derived PVR
alculation may be misleading because the inherent assump-
ions of linearity and zero crossing of the (PAPm 
CWP)/CO relationship are not met (28). It can indeed be mhown that multipoint (PAPm  PCWP)/CO coordinates
re described by a linear approximation, but present with a
ositive extrapolated pressure intercept (29,30). Single-
oint PVR determinations at variable flow therefore may
nderestimate or overestimate changes in the pulmonary
irculation (28). These errors can be avoided by defining
VR along a multipoint pressure/flow line (28).
Recent studies have shown that improvement in exercise
apacity with prostacyclin therapy may not be associated
ith significant changes in pulmonary hemodynamics at
est, whereas PVR defined by a multipoint (PAPm 
CWP)/CO plot shows a significant decrease with therapy
30). Using such a model, variation in flow can be achieved
ith exercise (30) or with an infusion of low-dose dobut-
mine (29).
Taken together, right heart catheterization with pulmo-
ary hemodynamic measurements remains central in the
iagnosis of PAH, in the evaluation of severity, response to
herapy, and prognosis in patients with PAH. Right heart
atheterization should therefore remain an essential part of
linical trials. However, in contrast to previous studies,
nless there is evidence of severe right heart dysfunction
recurrent syncope, cardiac index1.5 l/min/m2, right atrial
ressure 20 mm Hg), pulmonary hemodynamics should
e measured both at rest and during exercise to define PVR
y defining at least a two-point pulmonary vascular pres-
ure/flow relationship.
uality of life. At present, the objective of patient man-
gement in individuals with PAH is to improve survival and
oL. In an attempt to assess the impact of the condition on
atients’ QoL, generic health status measures, or health-
elated quality of life indicators such as the SF-36 (31),
ottingham Health Profile (32), Minnesota Living with
eart Failure Questionnaire (33), and EuroQoL (34) have
een used in studies of PAH. However, these measures
ssess impairment and disability rather than QoL, and their
eneric content is too general to provide valid and sensitive
ssessments. Furthermore, such instruments fail to assess
hose issues that are of major concern to the QoL of patients
35).
Unlike impairment and disability, QoL questionnaires
ummarize the impact of both the disease and its treatment
n the patient in a single score. The most widely operation-
lized model of QoL assessment postulates that QoL is the
xtent to which patients are able to meet their needs (36).
his model goes beyond an assessment of impairment and
isability by inquiring how impaired function affects pa-
ients’ ability to satisfy their needs. Major developments
ave been made in the science of QoL assessment (37);
owever, these are only now starting to be applied in PAH.
n these developments, emphasis is being placed on disease-
pecific measurements, with the content of instruments
erived directly from patients, thereby taking account of the
pecific and unique impact of PAH (38).
Work is currently in progress to develop two new instru-
ents specific to PAH, derived from qualitative, unstruc-
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June 18, 2004:48S–55S Trial Designs in PAHured interviews with PAH patients. One instrument is
esigned to assess impairment and disability (i.e., health
tatus or health-related QoL) with particular relevance to
AH. The second is a “needs”-based QoL measure specific
o PAH. The former assesses overall impairment, breath-
essness, edema, energy level, mood, and physical func-
ioning. Such disease-specific measures also increase the
otential for determining disease-specific utility and, con-
equently, determining the cost-effectiveness of clinical
nterventions. Once thoroughly evaluated, QoL assessments
ay be useful as primary or secondary end points in clinical
tudies on PAH.
chocardiography. Echocardiography is the most widely
vailable and versatile imaging test. Current data indicate
hat three groups of echocardiographic variables could be
otentially useful as end points in PAH. Interestingly,
ather than reflecting instantaneous hemodynamics such as
ight heart pressures and flows, most of those echocardio-
raphic variables reflect chronic consequences of PAH such
s: 1) elevated right atrial pressure as evidenced by the
resence and size of pericardial effusions (39,40) and by the
ight atrial area/volume (39,41); 2) RV dysfunction, mea-
ured by the Doppler Tei index of myocardial performance
r its surrogates (42); and 3) decreased left ventricular (LV)
reload, measured by assessing LV eccentricity index or end
iastolic area/volume. According to existing evidence, the
mprovement in LV diastolic dysfunction especially assessed
y decreased LV early diastolic filling velocity seems to best
eflect the effects of PAH treatment upon echocardio-
raphic measures (39). Most of the variables listed above are
imple and easy to obtain from a single apical four-chamber
iew in patients with PAH.
Tissue Doppler imaging (43) at echocardiography may
urther simplify the assessment of cardiac dynamics, by
roviding an assessment of the Tei index from a single
racing. It may also help to break down the Tei index,
llowing for separate assessment of RV systolic and diastolic
sovolumic time intervals. Also, simple measurements of the
uration and flow velocity pattern of RV ejection seem to
orrelate with results of treatment (39). Recent experimental
ata suggest that myocardial acceleration during isovolumic
V contraction is load-independent, and strongly correlates
ith end-systolic RV elastance, the best available measure of
V contractility (44).
Stress studies using dobutamine infusions or exercise may
elp to increase the sensitivity of detecting abnormal hemo-
ynamics and of following up the effects of treatment.
nfortunately, there is very limited experience with this
ype of assessment in patients with PAH (45,46).
Although several imaging-based signs have been shown to
orrelate with indices of functional capacity and survival and
ave been found to correlate with successful treatment
39,41,47,48), at present none seem suitable for recommenda-
ion as a single or primary end point in PAH. Nevertheless, an
chocardiographic substudy of the Bosentan Randomized trial
f Endothelin Antagonist Therapy (BREATHE)-1 PAH rreatment trial (2) performed in centers with substantial expe-
ience with this technique provided very useful information
alidating clinical benefits seen from treatment by showing
arallel improvement in several echocardiographic variables
39). This study may serve as a model for including echocar-
iographic parameters as secondary end points in future clinical
tudies.
ormonal and blood studies. Several biological markers
ave been used to aid in our understanding of the patho-
hysiology of PAH. Despite reports indicating that some
iochemical markers may be indicative of poorer survival,
hese markers have not been included in clinical trials in
AH.
An ideal marker for PAH would be heart-lung specific,
bnormal in PAH, easy to collect, easy to measure, and be
eproducible; it should also allow patient monitoring (it
hanges in one direction if patients deteriorate and in the
ther direction if patients improve), and it should also
redict survival. Among the markers that have previously
een studied, BNP, uric acid, and the troponins may be the
est candidates.
Brain natriuretic peptide is mostly secreted by overloaded
yocytes of the ventricles (49). Nagaya et al. (50,51) have
ound that initial and follow-up supramedian BNP plasma
evels were independent markers of prognosis in PAH. The
T-pro BNP (its biologically inactive alternative) is a more
table marker, which may be easier to study (49). Based on
he available data, BNP should be included as a secondary
nd point in upcoming clinical trials on patients with
dvanced PAH.
Troponin T is another biochemical marker that has
ecently been linked to the prognosis of PAH (52). Chronic
eakage of troponin T can be detected with high-sensitivity
ests in a subset of patients with severe pulmonary hyper-
ension. In contrast to other markers, troponin T is indic-
tive of ongoing damage of RV contractile proteins, which
ay contribute to progressive RV failure. Preliminary stud-
es by Torbicki et al. (52) have suggested that elevation of
roponin T was related to poor survival in PAH. They also
oted that troponin leakage may disappear with successful
reatment as well as appear with progression of the disease.
f these findings can be confirmed by larger studies, tropo-
in T may also be a useful secondary end point in trials
nvolving patients with advanced PAH.
Serum uric acid levels correlate inversely with cardiac
ndex and positively with right atrial pressure and PVR
53–55). Baseline and follow-up analyses of this marker
ndicate that it is related to survival and that hemodynamic
mprovements are associated with a decrease in uric acid
evels (55). This marker is, however, affected by several
ariables, including drugs, tissue perfusion, decreased glo-
erular filtration, and hypoxia. Therefore, intra- and inter-
ndividual variability of serum uric acid levels may be too
igh to render this parameter useful for clinical trials.
onclusions. Although short-term placebo-controlled andandomized trials are still feasible for assessing the efficacy
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ion studies of longer duration will likely be needed in the
uture. In patients with moderate to severe functional
mpairment, the 6-min walk test will probably remain
idely used as primary end point for proving efficacy of new
reatments. However, in patients with milder functional
mpairment, and for longer trials involving patients with
dvanced disease (comparative or combination studies),
ailure-free survival as defined above may become the most
eaningful end point. Hemodynamic variables remain very
seful as secondary end points, but in future trials these
easurements should be obtained at rest and during exercise
rovided that there are no signs of advanced right heart
ailure. In addition, imaging studies (e.g., echocardiography
nd possibly magnetic resonance imaging) should be in-
luded in clinical trials. It is also important that PAH-
pecific QoL questionnaires be developed and tested. The
sefulness of biochemical variables such as BNP or troponin
should be studied by including these parameters as
econdary end points, and a similar approach may be
tilized to establish the role of cardiopulmonary exercise
esting in randomized clinical trials.
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